no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
1 |
Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies
|
Ciccarese, Chiara |
|
2017 |
83 |
C |
p. 237-246 10 p. |
article |
2 |
Amide proton transfer-weighted magnetic resonance image-guided stereotactic biopsy in patients with newly diagnosed gliomas
|
Jiang, Shanshan |
|
2017 |
83 |
C |
p. 9-18 10 p. |
article |
3 |
A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma
|
Vergote, Ignace B. |
|
2017 |
83 |
C |
p. 229-236 8 p. |
article |
4 |
A prediction model for treatment decisions in high-grade extremity soft-tissue sarcomas: Personalised sarcoma care (PERSARC)
|
van Praag, Veroniek M. |
|
2017 |
83 |
C |
p. 313-323 11 p. |
article |
5 |
A randomised phase II study of continuous versus stop-and-go S-1 plus oxaliplatin following disease stabilisation in first-line chemotherapy in patients with metastatic gastric cancer
|
Park, Sook Ryun |
|
2017 |
83 |
C |
p. 32-42 11 p. |
article |
6 |
Association of the oestrogen receptor beta with hormone status and prognosis in a cohort of female patients with colorectal cancer
|
Topi, Geriolda |
|
2017 |
83 |
C |
p. 279-289 11 p. |
article |
7 |
A systematic review of the quality of statistical methods employed for analysing quality of life data in cancer randomised controlled trials
|
Hamel, Jean-Francois |
|
2017 |
83 |
C |
p. 166-176 11 p. |
article |
8 |
Breast cancer in South-Eastern European countries since 2000: Rising incidence and decreasing mortality at young and middle ages
|
Dimitrova, Nadya |
|
2017 |
83 |
C |
p. 43-55 13 p. |
article |
9 |
Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial
|
Ferry, David |
|
2017 |
83 |
C |
p. 302-312 11 p. |
article |
10 |
Clinically meaningful benefit: Half of the value equation
|
Sullivan, Richard |
|
2017 |
83 |
C |
p. 329-330 2 p. |
article |
11 |
Colorectal cancer risk associated with the CHEK2 1100delC variant
|
Katona, Bryson W. |
|
2017 |
83 |
C |
p. 103-105 3 p. |
article |
12 |
Corrigendum to “Nuclear transportation of exogenous epidermal growth factor receptor and androgen receptor via extracellular vesicles” [Eur J Cancer 70 (2017) 62–74]
|
Read, Jolene |
|
2017 |
83 |
C |
p. 335- 1 p. |
article |
13 |
Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma
|
Lohneis, Philipp |
|
2017 |
83 |
C |
p. 290-301 12 p. |
article |
14 |
Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancer
|
Michielsen, Katrijn |
|
2017 |
83 |
C |
p. 88-98 11 p. |
article |
15 |
Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma
|
Ugurel, Selma |
|
2017 |
83 |
C |
p. 142-145 4 p. |
article |
16 |
Inhibition of lymphangiogenesis impairs antitumour effects of photodynamic therapy and checkpoint inhibitors in mice
|
Muchowicz, Angelika |
|
2017 |
83 |
C |
p. 19-27 9 p. |
article |
17 |
Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study
|
Morel, Alexandre |
|
2017 |
83 |
C |
p. 146-153 8 p. |
article |
18 |
Medical treatment of advanced chordomas
|
Colia, Vittoria |
|
2017 |
83 |
C |
p. 220-228 9 p. |
article |
19 |
Medication use and kidney cancer risk: A population-based study
|
Nayan, Madhur |
|
2017 |
83 |
C |
p. 203-210 8 p. |
article |
20 |
Multidisciplinary training of cancer specialists in Europe
|
Benstead, Kim |
|
2017 |
83 |
C |
p. 1-8 8 p. |
article |
21 |
Mutant p53 as a target for cancer treatment
|
Duffy, Michael J. |
|
2017 |
83 |
C |
p. 258-265 8 p. |
article |
22 |
Neoadjuvant chemoradiotherapy for oesophageal cancer: Still looking for a challenger to the CROSS regimen
|
Adenis, Antoine |
|
2017 |
83 |
C |
p. 331-332 2 p. |
article |
23 |
New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors
|
Golob-Schwarzl, Nicole |
|
2017 |
83 |
C |
p. 56-70 15 p. |
article |
24 |
Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study)
|
Chisholm, Julia C. |
|
2017 |
83 |
C |
p. 177-184 8 p. |
article |
25 |
P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition
|
Najem, Ahmad |
|
2017 |
83 |
C |
p. 154-165 12 p. |
article |
26 |
Primary metastatic breast cancer in the era of targeted therapy – Prognostic impact and the role of breast tumour surgery
|
Barinoff, Jana |
|
2017 |
83 |
C |
p. 116-124 9 p. |
article |
27 |
Prognostic value of the G8 and modified-G8 screening tools for multidimensional health problems in older patients with cancer
|
Martinez-Tapia, Claudia |
|
2017 |
83 |
C |
p. 211-219 9 p. |
article |
28 |
Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: Case report and review of the literature
|
Deinlein, Teresa |
|
2017 |
83 |
C |
p. 99-102 4 p. |
article |
29 |
RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study
|
Massard, Christophe |
|
2017 |
83 |
C |
p. 185-193 9 p. |
article |
30 |
Response to: Neoadjuvant chemoradiotherapy for oesophageal cancer: Still looking for a challenger to the CROSS regimen
|
Mukherjee, Somnath |
|
2017 |
83 |
C |
p. 333-334 2 p. |
article |
31 |
Risk of treatment-related mortality in cancer patients treated with ipilimumab: A systematic review and meta-analysis
|
Zhang, Sheng |
|
2017 |
83 |
C |
p. 71-79 9 p. |
article |
32 |
Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy
|
Boisseau, W. |
|
2017 |
83 |
C |
p. 28-31 4 p. |
article |
33 |
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study
|
Angevin, Eric |
|
2017 |
83 |
C |
p. 194-202 9 p. |
article |
34 |
Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo
|
Murray, Jayne |
|
2017 |
83 |
C |
p. 132-141 10 p. |
article |
35 |
Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group
|
Penel, Nicolas |
|
2017 |
83 |
C |
p. 125-131 7 p. |
article |
36 |
Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017
|
Ugurel, Selma |
|
2017 |
83 |
C |
p. 247-257 11 p. |
article |
37 |
The urgent need to improve the tools to assess clinical benefit and value of cancer treatment
|
Sobrero, Alberto |
|
2017 |
83 |
C |
p. 324-328 5 p. |
article |
38 |
Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients
|
Heestand, Gregory M. |
|
2017 |
83 |
C |
p. 80-87 8 p. |
article |
39 |
Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations – Still a daily challenge
|
Su, Chunxia |
|
2017 |
83 |
C |
p. 266-278 13 p. |
article |
40 |
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients
|
Cascinu, Stefano |
|
2017 |
83 |
C |
p. 106-115 10 p. |
article |